El-Derany M O, Hamdy N M, Al-Ansari N L, El-Mesallamy H O
Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Endemic Medicine Department & Hepatology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
BMC Gastroenterol. 2016 Feb 24;16:19. doi: 10.1186/s12876-016-0440-5.
Improving prediction of treatment outcomes in chronic hepatitis C (CHC) genotype 4 (G4) is necessary to increase sustained viral response (SVR) rates. Vitamin D related and interferon stimulated genes are good candidates as they are recently crosstalk altering interferon response. Thus single nucleotide polymorphisms (SNPs) within some of these genes and multiple stepwise regression analysis including other independent predictors (IL28B(rs12979860), serum 25OH-vitamin D, serum alfa-fetoprotein (AFP)) were performed on a cohort of 200 Egyptian CHC patients treated with Pegylated interferon-alpha (Peg-IFN) plus ribavirin.
SNPs in cytochrome P-450 (CYP2R1)(rs10741657AG), vitamin D receptor (VDR)(rs2228570AG, rs1544410CT), oligoadenylate synthetases-like (OASL)(rs1169279CT) and adenosine deaminases acting on RNA (ADAR)(rs1127309TC) genes were analyzed by real-time PCR.
The carrier state of A allele in VDR rs2228570 and CYP2R1 rs10741657 genes were independently associated with SVR [OR 6.453 & 3.536, p < 0.01 respectively]. Combining carriers of A allele in CYP2R1 and VDR genes with IL28B C/C genotype increased the probability of SVR from 80 % to reach 87.8 %, 93 % and 100 %. No relation was found between VDR rs1544410CT, ADAR rs1127309TC, OASL rs1169279CT polymorphisms and treatment outcome. Combining VDR rs2228570 A/A genotype with IL28B C/C genotype increased the probability of SVR from 82 % to reach 100 % and from 29 % to reach 80 % in C/T+ T/T IL28B genotype in none F4 liver disease patients.
Vitamin D related (VDR rs2228570 and CYP2R1 rs10741657) and IL28B rs12979860 genes polymorphisms accurately assure SVR in naïve CHC G4 patients treated with low cost standard therapy.
提高对慢性丙型肝炎(CHC)基因4型(G4)治疗结果的预测对于提高持续病毒学应答(SVR)率很有必要。维生素D相关基因和干扰素刺激基因是很好的候选基因,因为它们最近存在改变干扰素应答的相互作用。因此,对200例接受聚乙二醇化干扰素-α(Peg-IFN)加利巴韦林治疗的埃及CHC患者队列进行了这些基因中的一些单核苷酸多态性(SNP)以及包括其他独立预测因子(IL28B(rs12979860)、血清25羟维生素D、血清甲胎蛋白(AFP))的多步回归分析。
通过实时PCR分析细胞色素P-450(CYP2R1)(rs10741657AG)、维生素D受体(VDR)(rs2228570AG、rs1544410CT)、寡腺苷酸合成酶样(OASL)(rs1169279CT)和作用于RNA的腺苷脱氨酶(ADAR)(rs1127309TC)基因中的SNP。
VDR rs2228570和CYP2R1 rs10741657基因中A等位基因的携带状态与SVR独立相关[OR分别为6.453和3.536,p<0.01]。将CYP2R1和VDR基因中A等位基因的携带者与IL28B C/C基因型相结合,使SVR的概率从80%提高到87.8%、93%和100%。未发现VDR rs1544410CT、ADAR rs1127309TC、OASL rs1169279CT多态性与治疗结果之间的关系。在无F4期肝病患者中,将VDR rs2228570 A/A基因型与IL28B C/C基因型相结合,使SVR的概率从82%提高到100%,在C/T+T/T IL28B基因型中从29%提高到80%。
维生素D相关基因(VDR rs2228570和CYP2R1 rs10741657)和IL28B rs12979860基因多态性可准确确保初治CHC G4患者采用低成本标准治疗时获得SVR。